Anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphomas (PTCLs) represent biologically and clinically heterogeneous subsets of mature T-cell malignancies associated with poor prognoses and limited therapeutic options. Despite advances in the molecular understanding of these lymphomas, conventional chemotherapy regimens such as CHOP remain suboptimal, with high relapse rates and inferior survival compared to B-cell counterparts. The identification of recurrent genetic alterations, dysregulated signaling pathways, and distinct immune microenvironment profiles has expanded our knowledge of disease pathogenesis. Recent progress in targeted therapies, antibody–drug conjugates, immune modulation, and cellular therapies is reshaping the treatment landscape. Continued translational research and clinical innovation are essential to improving outcomes and personalizing therapy for patients with ALCL and PTCL.

This Research Topic aims to explore evolving therapeutic strategies for ALCL and PTCL, focusing on the integration of molecular insights with clinical innovation. The goal is to highlight advances that address the unmet need for effective, durable, and less toxic treatments. Contributions may include original research, reviews, and perspectives on novel targeted agents (e.g., ALK inhibitors, PI3K inhibitors, JAK/STAT pathway modulators), antibody–drug conjugates such as brentuximab vedotin, immune checkpoint inhibitors, CAR T-cell or bispecific antibody therapies, and hematopoietic cell transplantation. In addition, studies on predictive biomarkers, mechanisms of resistance, and the role of tumor microenvironment will be encouraged. By consolidating recent discoveries and emerging clinical evidence, this collection seeks to guide future research directions and foster research in treatment approaches for adult and pediatric patients with this set of diseases.

We welcome Original Research, Review, Mini Review and Perspective articles on themes including, but not limited to:
• Molecular and genomic profiling
• Dysregulated signaling pathways and mechanisms of resistance
• Biomarker discovery and prognostic stratification
• Tumor microenvironment and immune landscape
• Emerging targeted therapies and antibody–drug conjugates
• Novel immunotherapies (checkpoint inhibitors, CAR-T, bispecific antibodies)
• Hematopoietic cell transplantation
• Combination treatment strategies

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Are you interested in contributing a manuscript to this Research Topic?

Anaplastic Large Cell Lymphoma and Peripheral T-cell Lymphomas: Evolving Therapeutic Strategies